Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer

Table 3

Number of patients who experienced a grade 3 or 4 toxicity.

NCI-CTCAE grade 3-4 toxicity	Grade 3	Grade 4
Hematological toxicity
Anemia	3 (7.0%)	1 (2.3%)
Leucopenia	1 (2.3%)	2 (4.7%)
Neutropenia	5 (11.6%)	3 (7.0%)
Thrombocytopenia	1 (2.3%)	0 (0.0%)
Nonhematological toxicity
Fatigue	9 (20.5%)	0 (0.0%)
Nausea	2 (4.5%)	0 (0.0%)
Diarrhea	5 (11.4%)	1 (2.3%)
Vomiting	3 (6.8%)	0 (0.0%)
Anorexia	2 (4.5%)	0 (0.0%)
Mucositis/stomatitis	2 (4.5%)	0 (0.0%)
Dehydration	2 (4.5%)	0 (0.0%)
Febrile neutropenia	1 (2.3%)	0 (0.0%)
Infection	0 (0.0%)	1 (2.3%)
Rash	1 (2.3%)	0 (0.0%)
Biochemistry
ALAT increase	4 (9.5%)	0 (0.0%)
Hyperbilirubinemia	2 (4.8%)	0 (0.0%)
Hypokalemia	2 (4.8%)	0 (0.0%)
Alkaline phosphatase	1 (2.4%)	0 (0.0%)
Hyponatremia	1 (2.4%)	0 (0.0%)

Abbreviations: NCI-CTCAE: National Cancer Institute-Common Terminology Criteria for Adverse Events; ALAT: alanine aminotransferase.